{"id":"anti-ngf-ab","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"5%","effect":"Headache"},{"rate":"5%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-NGF AB works by blocking the action of nerve growth factor, a protein involved in the growth and maintenance of nerve cells.","oneSentence":"Antagonist of nerve growth factor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:07.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT00830180","phase":"PHASE2","title":"Open Label Extension In Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":"Neoplasms, Bone Metastases","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-NGF AB","genericName":"Anti-NGF AB","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Anti-NGF AB is being studied in clinical trials for the treatment of Neoplasms and Bone Metastases. The primary purpose of these trials is to assess the safety of Anti-NGF AB in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}